Cell and Gene Therapy Funding Totaled $40 Billion in 2022, Growth Projected

Cell and gene therapy is attracting much attention these days and for good reason.  For one, there has been a notable increase in the number of cell and gene therapies in clinical development over the past decade. In the United States alone there are over 1,000 cell and gene therapies in clinical development, and more than three times as many in pre-clinical development. But clinical and pre-clinical activity is only part of the reason to be excited about the market, considering that cell and gene therapy-related companies received more than $40 billion in funding in 2022, according to leading medical market research firm Kalorama Information.

The findings were published in Kalorama Information’s latest report Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals. The report features Kalorama Information’s unique and exclusive deals tracker covering cell and gene therapy financing, collaborations, and other deals from Q1 2021-Q1 2023. The analysis is based on 1000+ deals from 2022-2023, the specific details of which are all included in the report.  Deals prior to 2022 are also tabulated to present chronological trends from 2021-2023.

While the concepts of gene therapy and cell therapy have been investigated for decades, there were major challenges in the early years.  Through incremental progress, and the gradual introduction of enabling tools such as CRISPR and next-generation sequencing (NGS), cell and gene therapy has emerged into a highly active area.  There are now many approved therapies with proven track records.  As the new tools have lowered the barriers to entry for the industry, over 1,500 companies have been created or have become involved.

Total annual cell and gene funding in 2022 dropped from around $70 billion in 2021. Partly the decrease was due to the tighter funding environment that has been seen across other industries.  Some types of deals, such as collaborations and acquisitions, continue to increase significantly.  The rate of new manufacturing/supply chain deals also approximately doubled.  VC/private funding deals have remained at roughly the same number, although the dollar amount has dropped.  The number of public offerings/SPAC deals went down in early 2022 but then grew consistently in the time since.  Licensing deals have increased. Also IPOs/FPOs were initially negligible in early 2022 but have almost fully recovered in the year since.  In practical terms, for cell and gene therapy companies being mostly startups, this tighter funding has been experienced as a lower average funding round for VC/private funding, while the number of those deals has remained somewhat consistent.

Total Number of VC/Private Funding Deals by Month, January 2021-March 2023 (Total count)

“Cell and gene therapy-related companies have continued to receive huge amounts of investment. And despite slight fluctuations year-to-year, there’s a lot of reasons to conclude that funding in cell and gene therapies will only strengthen in coming years,” says Bruce Carlson, publisher for Kalorama Information.

Further evidence of the market’s growth momentum is linked to comments by Peter Marks of the U.S. Food and Drug Administration (FDA), who in March 2023 expressed a desire to boost commercialization for cell and gene therapies for patients with rare diseases by aligning global regulations.

At the Reuters Pharma USA conference in March in Philadelphia, Marks commented: “If you could have a way of having the EU, U.S., Japan, Canada, perhaps Switzerland all have approvals at close to the same time, that would give a market that would be four or five times as large as just the U.S.”

For more information or to purchase the market research report “Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals”, visit https://kaloramainformation.com/product/cell-and-gene-therapy-market-and-deals-analysis-2023-financings-partnering-mergers-and-acquisitions-tech-transfers-ipos-and-other-deals/.  

Why Choose Kalorama Information?  

Each Kalorama Information study features independent primary research conducted by experienced analysts. Researchers build their market analysis independently from published databases, validating data with inside industry contacts and extensive secondary research, so you can have confidence that you’re getting your information from the most trusted source in the industry!